177 related articles for article (PubMed ID: 24193916)
1. Targeting elongation factor-2 kinase (eEF-2K) induces apoptosis in human pancreatic cancer cells.
Ashour AA; Abdel-Aziz AA; Mansour AM; Alpay SN; Huo L; Ozpolat B
Apoptosis; 2014 Jan; 19(1):241-58. PubMed ID: 24193916
[TBL] [Abstract][Full Text] [Related]
2. Elongation factor-2 kinase regulates TG2/β1 integrin/Src/uPAR pathway and epithelial-mesenchymal transition mediating pancreatic cancer cells invasion.
Ashour AA; Gurbuz N; Alpay SN; Abdel-Aziz AA; Mansour AM; Huo L; Ozpolat B
J Cell Mol Med; 2014 Nov; 18(11):2235-51. PubMed ID: 25215932
[TBL] [Abstract][Full Text] [Related]
3. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells.
Singh BN; Kumar D; Shankar S; Srivastava RK
Biochem Pharmacol; 2012 Nov; 84(9):1154-63. PubMed ID: 22902833
[TBL] [Abstract][Full Text] [Related]
4. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer.
Bircan HA; Gurbuz N; Pataer A; Caner A; Kahraman N; Bayraktar E; Bayraktar R; Erdogan MA; Kabil N; Ozpolat B
Lung Cancer; 2018 Oct; 124():31-39. PubMed ID: 30268477
[TBL] [Abstract][Full Text] [Related]
5. Combined treatment of mitoxantrone sensitizes breast cancer cells to rapalogs through blocking eEF-2K-mediated activation of Akt and autophagy.
Guan Y; Jiang S; Ye W; Ren X; Wang X; Zhang Y; Yin M; Wang K; Tao Y; Yang J; Cao D; Cheng Y
Cell Death Dis; 2020 Nov; 11(11):948. PubMed ID: 33144562
[TBL] [Abstract][Full Text] [Related]
6. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer.
Kabil N; Bayraktar R; Kahraman N; Mokhlis HA; Calin GA; Lopez-Berestein G; Ozpolat B
Breast Cancer Res Treat; 2018 Oct; 171(3):593-605. PubMed ID: 29971628
[TBL] [Abstract][Full Text] [Related]
7. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer.
Tekedereli I; Alpay SN; Tavares CD; Cobanoglu ZE; Kaoud TS; Sahin I; Sood AK; Lopez-Berestein G; Dalby KN; Ozpolat B
PLoS One; 2012; 7(7):e41171. PubMed ID: 22911754
[TBL] [Abstract][Full Text] [Related]
8. What is the impact of eukaryotic elongation factor 2 kinase on cancer: A systematic review.
Li S; Li Y; Bai Y
Eur J Pharmacol; 2019 Aug; 857():172470. PubMed ID: 31226250
[TBL] [Abstract][Full Text] [Related]
9. Eukaryotic elongation factor-2 kinase regulates the cross-talk between autophagy and pyroptosis in doxorubicin-treated human melanoma cells in vitro.
Yu P; Wang HY; Tian M; Li AX; Chen XS; Wang XL; Zhang Y; Cheng Y
Acta Pharmacol Sin; 2019 Sep; 40(9):1237-1244. PubMed ID: 30914761
[TBL] [Abstract][Full Text] [Related]
10. Rottlerin sensitizes colon carcinoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis via uncoupling of the mitochondria independent of protein kinase C.
Tillman DM; Izeradjene K; Szucs KS; Douglas L; Houghton JA
Cancer Res; 2003 Aug; 63(16):5118-25. PubMed ID: 12941843
[TBL] [Abstract][Full Text] [Related]
11. Structure of the complex between calmodulin and a functional construct of eukaryotic elongation factor 2 kinase bound to an ATP-competitive inhibitor.
Piserchio A; Isiorho EA; Dalby KN; Ghose R
J Biol Chem; 2023 Jun; 299(6):104813. PubMed ID: 37172726
[TBL] [Abstract][Full Text] [Related]
12. Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact.
Devkota AK; Tavares CD; Warthaka M; Abramczyk O; Marshall KD; Kaoud TS; Gorgulu K; Ozpolat B; Dalby KN
Biochemistry; 2012 Mar; 51(10):2100-12. PubMed ID: 22352903
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of eEF-2 kinase sensitizes human glioma cells to TRAIL and down-regulates Bcl-xL expression.
Zhang Y; Cheng Y; Zhang L; Ren X; Huber-Keener KJ; Lee S; Yun J; Wang HG; Yang JM
Biochem Biophys Res Commun; 2011 Oct; 414(1):129-34. PubMed ID: 21945617
[TBL] [Abstract][Full Text] [Related]
14. Novel compounds, '1,3-selenazine derivatives' as specific inhibitors of eukaryotic elongation factor-2 kinase.
Cho SI; Koketsu M; Ishihara H; Matsushita M; Nairn AC; Fukazawa H; Uehara Y
Biochim Biophys Acta; 2000 Jul; 1475(3):207-15. PubMed ID: 10913818
[TBL] [Abstract][Full Text] [Related]
15. Phosphorylation of elongation factor-2 kinase differentially regulates the enzyme's stability under stress conditions.
Huber-Keener KJ; Evans BR; Ren X; Cheng Y; Zhang Y; Hait WN; Yang JM
Biochem Biophys Res Commun; 2012 Jul; 424(2):308-14. PubMed ID: 22749997
[TBL] [Abstract][Full Text] [Related]
16. The molecular mechanism of eukaryotic elongation factor 2 kinase activation.
Tavares CD; Ferguson SB; Giles DH; Wang Q; Wellmann RM; O'Brien JP; Warthaka M; Brodbelt JS; Ren P; Dalby KN
J Biol Chem; 2014 Aug; 289(34):23901-16. PubMed ID: 25012662
[TBL] [Abstract][Full Text] [Related]
17. Structure prediction of eukaryotic elongation factor-2 kinase and identification of the binding mechanisms of its inhibitors: homology modeling, molecular docking, and molecular dynamics simulation.
Tatar G; Taskin Tok T; Ozpolat B; Ay M
J Biomol Struct Dyn; 2022; 40(24):13355-13365. PubMed ID: 30880628
[TBL] [Abstract][Full Text] [Related]
18. Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli.
Abramczyk O; Tavares CD; Devkota AK; Ryazanov AG; Turk BE; Riggs AF; Ozpolat B; Dalby KN
Protein Expr Purif; 2011 Oct; 79(2):237-44. PubMed ID: 21605678
[TBL] [Abstract][Full Text] [Related]
19. Rottlerin induces apoptosis via death receptor 5 (DR5) upregulation through CHOP-dependent and PKC delta-independent mechanism in human malignant tumor cells.
Lim JH; Park JW; Choi KS; Park YB; Kwon TK
Carcinogenesis; 2009 May; 30(5):729-36. PubMed ID: 19037087
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting eEF-2 kinase-mediated autophagy enhanced the cytocidal effect of AKT inhibitor on human nasopharyngeal carcinoma.
Zhao YY; Tian Y; Liu L; Zhan JH; Hou X; Chen X; Zhou T; Huang Y; Zhang L
Drug Des Devel Ther; 2018; 12():2655-2663. PubMed ID: 30214154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
